AbbVie (NYSE:ABBV) Issues FY 2025 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 10.380-10.580 for the period, compared to the consensus EPS estimate of 11.990. The company issued revenue guidance of -. AbbVie also updated its Q3 2025 guidance to 1.740-1.780 EPS.

AbbVie Price Performance

NYSE:ABBV opened at $234.07 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The company has a market capitalization of $413.49 billion, a P/E ratio of 111.46, a P/E/G ratio of 1.38 and a beta of 0.51. AbbVie has a 12 month low of $163.81 and a 12 month high of $244.81. The business’s 50-day moving average is $210.77 and its 200 day moving average is $196.01.

AbbVie (NYSE:ABBV) last posted its earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts’ consensus estimates of $3.24 by ($0.27). The firm had revenue of $15.42 billion during the quarter, compared to analysts’ expectations of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.65 earnings per share. On average, equities research analysts forecast that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 14th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, October 15th. AbbVie’s payout ratio is presently 312.38%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ABBV shares. JPMorgan Chase & Co. boosted their price objective on AbbVie from $200.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Saturday, September 27th. Guggenheim boosted their price objective on AbbVie from $216.00 to $227.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Finally, Wells Fargo & Company boosted their price objective on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $228.22.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the transaction, the executive vice president owned 58,247 shares of the company’s stock, valued at $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. This trade represents a 19.29% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. grew its stake in AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares in the last quarter. Corient Private Wealth LLC lifted its holdings in AbbVie by 3.9% during the second quarter. Corient Private Wealth LLC now owns 2,380,205 shares of the company’s stock worth $442,528,000 after buying an additional 90,160 shares during the period. Captrust Financial Advisors lifted its holdings in AbbVie by 3.7% during the second quarter. Captrust Financial Advisors now owns 1,436,527 shares of the company’s stock worth $266,648,000 after buying an additional 51,551 shares during the period. Worldquant Millennium Advisors LLC lifted its holdings in AbbVie by 117.3% during the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after buying an additional 612,702 shares during the period. Finally, State of Tennessee Department of Treasury lifted its holdings in AbbVie by 4.8% during the second quarter. State of Tennessee Department of Treasury now owns 656,273 shares of the company’s stock worth $121,817,000 after buying an additional 30,199 shares during the period. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.